Update shared on21 Aug 2025
Fair value Decreased 12%The Analyst Price Target for Waldencast was reduced to $3.50 from $3.98, reflecting concerns about softer international demand, operational disruptions, strategic uncertainty, and delayed reporting, despite some positive momentum at core brands.
Analyst Commentary
- Moderated annual outlook due to softening international consumption and out-of-stock issues at Waldencast brands.
- Exiting non-core distribution points at Obagi negatively impacting growth projections.
- Strategic uncertainties heightened by the exploration of potential business alternatives.
- Postponement of 1H25 financial reporting contributing to reduced investor confidence and increased risk perception.
- Positive underlying trends include sell-through momentum at Milk in the US and sequential improvement in Obagi’s core operations.
What's in the News
- Waldencast updated its full-year 2025 earnings guidance, now expecting net revenue growth in the low to mid-single digits, citing first-half performance and a moderated industry environment.
Valuation Changes
Summary of Valuation Changes for Waldencast
- The Consensus Analyst Price Target has significantly fallen from $3.98 to $3.50.
- The Consensus Revenue Growth forecasts for Waldencast has significantly fallen from 14.0% per annum to 10.2% per annum.
- The Future P/E for Waldencast has significantly fallen from 29.35x to 25.05x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.